Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | ARAF | P10398 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23111304 | 0.88 | TDP1 (0.67) | BRAFHDAC1ABL1KDM4EALDH1A1 | |
| SCHEMBL1026723 | 0.88 | BRAF (0.56) | BRAFHDAC1ABL1KDM4EALDH1A1 | |
| SCHEMBL2723179 | 0.86 | ALDH1A1 (0.57) | BRAFHDAC1KDM4EALDH1A1MAPT | |
| SCHEMBL267531 | 0.84 | ABL1 (0.74) | ABL1KDM4EALDH1A1MAPTHSD17B10 | |
| Hydrochloric Acid SCHEMBL2454106 | 0.84 | BRAF (0.57) | BRAFHDAC1ABL1KDM4EALDH1A1 | |
| SCHEMBL31352537 | 0.82 | ALDH1A1 (0.47) | BRAFHDAC1ABL1KDM4EALDH1A1 | |
| SCHEMBL31451790 | 0.82 | KDM4E (0.57) | ABL1KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL4264458 | 0.81 | ABL1 (0.61) | ABL1KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL1026672 | 0.81 | ALDH1A1 (0.54) | BRAFHDAC1KDM4EALDH1A1MAPT | |
| SCHEMBL34472980 | 0.81 | ABL1 (0.50) | BRAFHDAC1ABL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792251-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-3186227-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| EP-3792251-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Elanco Tiergesundheit AG (CH) | 2021-03-17 | — | — | EP | disclosed |
| CN-106660961-B | Sulfonylaminobenzamide compounds as anthelmintics | 瑞士伊兰科动物保健有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | ELANCO TIERGESUNDHEIT AG (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2017-08-10 | — | — | US | disclosed |
| EP-3186227-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033341-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-2990403-A1 | ANTHRANILAMIDES, SULFONAMIDES AND NITRO ANALOGUES DERIVED THEREFROM AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2016-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | BRAF 2853/4885HDAC1 334/4885ABL1 2016/4885 |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | PKD2, CATSPER1, ATP1B2 | BRAF 2130/4885HDAC1 261/4885ABL1 1625/4885 |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | BRAF 2853/4885HDAC1 334/4885ABL1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.